StockNews.AI

PainReform's LayerBio's Drop-Less OcuRing™-K Delivery Platform Demonstrates Favorable Safety Profile in Preclinical and Phase I Clinical Studies

StockNews.AI • 11 hours

LayerBio Inc.Zynerba Pharmaceuticals Inc.Eyenovia Inc.
High Materiality9/10

Information

TEL AVIV, Israel, Jan. 12, 2026 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), a clinical-stage...

Original source

AI Summary

OcuRing-K Phase I study showed no treatment-related safety concerns for cataract surgery. Favorable safety profiles in both preclinical and clinical studies support OcuRing-K advancement. PainReform is progressing toward IND submission for OcuRing-K platform. The drug delivery system aims to reduce pain management reliance on opioids. Positive outcomes could enhance PainReform's market position amid increasing surgical demand.

Sentiment Rationale

The safety data reinforces confidence prior to potential market introduction, similar to past successful drug developments. Other technologies with favorable clinical outcomes have historically led to stock rises.

Trading Thesis

Advancements in regulatory processes often lead to sustained stock performance over time, particularly with successful IND submissions.

Market-Moving

  • OcuRing-K Phase I study showed no treatment-related safety concerns for cataract surgery.
  • Favorable safety profiles in both preclinical and clinical studies support OcuRing-K advancement.
  • PainReform is progressing toward IND submission for OcuRing-K platform.

Key Facts

  • OcuRing-K Phase I study showed no treatment-related safety concerns for cataract surgery.
  • Favorable safety profiles in both preclinical and clinical studies support OcuRing-K advancement.
  • PainReform is progressing toward IND submission for OcuRing-K platform.
  • The drug delivery system aims to reduce pain management reliance on opioids.
  • Positive outcomes could enhance PainReform's market position amid increasing surgical demand.

Companies Mentioned

  • LayerBio Inc. (LayerBio Inc.)
  • Zynerba Pharmaceuticals Inc. (Zynerba Pharmaceuticals Inc.)
  • Eyenovia Inc. (Eyenovia Inc.)

Corporate Developments

The positive clinical results are critical as they can lead to future approvals and revenue generation.

PainReform's OcuRing™-K Delivery Platform Shows Strong Safety Results in Recent Trials

TEL AVIV, Israel, Jan. 12, 2026 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), a clinical-stage specialty pharmaceutical company, has reported favorable safety data for its innovative OcuRing™-K delivery platform designed for use in cataract surgery. These findings support the platform's advancement towards an Investigational New Drug (IND) submission, reflecting the company’s commitment to enhancing post-operative pain management solutions.

Comprehensive Study Highlights

The development program for OcuRing™-K included extensive preclinical rabbit studies evaluating ocular tolerability, biocompatibility, and tissue response, followed by a Phase I clinical trial with patients undergoing cataract surgery. The results from both studies demonstrated a favorable safety profile:

  • No treatment-related adverse events linked to OcuRing™-K were observed during the Phase I study.
  • All reported adverse events were consistent with expected outcomes of cataract surgery.
  • No serious adverse events were reported, confirming the drug delivery platform's safety.
  • Preclinical tests revealed no ocular tissue abnormalities when comparing OcuRing™-K to control groups.

Expert Insights on Safety Profile

Dr. Ehud Geller, Executive Chairman and interim CEO of PainReform, remarked, “The successful completion of both preclinical and Phase I safety evaluations represents a critical milestone for OcuRing-K™’s drop-less drug delivery platform. The consistent safety profile observed across animal models and human subjects validates our pursuit of this technology’s further development.” This consistent safety data positions PainReform favorably as they move toward late-stage development.

Innovative Drug Delivery Mechanism

The OcuRing™-K system utilizes a drop-less, sustained-release mechanism designed to deliver non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and other ophthalmic therapeutic agents through a single intraoperative application. This advanced formulation aims to:

  • Minimize local irritation.
  • Reduce epithelial toxicity.
  • Limit systemic exposure typical with conventional topical dosing regimens.

PainReform and LayerBio are actively engaged in IND-enabling activities, with preparation underway to support the next phase of clinical evaluations in the United States.

About PainReform

PainReform Ltd. (Nasdaq: PRFX) is a diversified innovation company dedicated to advancing specialty pharmaceutical therapies and AI-powered energy analytics. The company's pharmaceutical initiatives focus on reformulating established therapeutics to improve patient outcomes and decrease dependency on opioids. Additionally, through its DeepSolar platform, PainReform develops AI solutions to enhance monitoring and optimization of energy performance for solar asset owners.

Forward-Looking Statements

This press release contains forward-looking statements concerning PainReform’s expectations regarding its operations and product development. Such statements are subject to certain risks and uncertainties, which may lead to results materially different than anticipated. The company undertakes no obligation to revise any such statements based on new information or future events.

Contact Information

For additional inquiries:

Dr. Ehud Geller
Chairman and interim Chief Executive Officer
PainReform Ltd.
Tel: +972-54-4236711
Email: egeller@medicavp.com

Related News